{
    "title": "107_s2818",
    "content": "SECTION 1. SHORT TITLE.\n\n    This Act may be cited as the ``Timely Review and Increased Access \nto Affordable Drugs Act''.\n\nSEC. 2. 30-MONTH STAY-OF-EFFECTIVENESS PERIOD.\n\n    (a) In General.--Section 505(j) of the Federal Food, Drug, and \nCosmetic Act (21 U.S.C. 355(j)) is amended--\n            (1) in paragraph (2)(A)(vii)--\n                    (A) by striking ``a certification, the opinion of \n                the applicant and to the best of his knowledge,'' and \n                inserting ``a certification that, in the opinion of and \n                to the best knowledge of the applicant,''; and\n                    (B) by inserting after ``each patent'' the \n                following: ``published by the Secretary under \n                subsection (c)(2) at least 1 day before the date on \n                which the application is filed''; and\n            (2) in paragraph (5)--\n                    (A) in subparagraph (B)(iii)--\n                            (i) by inserting after ``of a patent'' the \n                        following: ``published by the Secretary under \n                        subsection (c)(2) at least 1 day before the \n                        date on which the application is filed'';\n                            (ii) by striking ``paragraph (2)(B)(i)'' \n                        each place it appears and inserting ``(2)(B)''; \n                        and\n                            (iii) by adding at the end the following: \n                        ``If, in connection with an application for \n                        approval of a drug under this subsection, the \n                        applicant provides an owner of a patent notice \n                        under paragraph (2)(B) with respect to the \n                        patent, and the owner of the patent fails to \n                        bring a civil action against the applicant for \n                        infringement of the patent on or before the \n                        date that is 45 days after the date on which \n                        the notice is received, the owner of the patent \n                        shall be barred from bringing a civil action \n                        against the applicant with respect to the \n                        application.'';\n                    (B) by redesignating subparagraphs (C) and (D) as \n                subparagraphs (E) and (F), respectively; and\n                    (C) by inserting after subparagraph (B) the \n                following:\n                    ``(C) Availability of 30-month period.--\n                            ``(i) In general.--The 30-month period \n                        provided under subparagraph (B)(iii) shall be \n                        available only with respect to patents \n                        published by the Secretary under subsection \n                        (c)(2) at least 1 day before the date on which \n                        the application is filed.\n                            ``(ii) Amendment of application.--If an \n                        application is amended to include a \n                        certification described in paragraph \n                        (2)(A)(vii)(IV), the 30-month period provided \n                        under subparagraph (B)(iii) shall be available \n                        with respect to the patent concerning which the \n                        certification was made.\n                            ``(iii) Subsequent patents.--\n                                    ``(I) Separate application.--Any \n                                patent published by the Secretary under \n                                subsection (c)(2) subsequent to the \n                                filing date but before approval of an \n                                application under this paragraph shall \n                                be addressed in a subsequent \n                                application if the subsequent applicant \n                                makes a certification described in \n                                subparagraph (2)(A)(vii)(IV) with \n                                respect to the patent, in which case \n                                the 30-month period provided under \n                                subparagraph (B)(iii) shall be \n                                available to the subsequently published \n                                patent.\n                                    ``(II) Referencing information in \n                                the previous application.--If a \n                                subsequent application is filed, the \n                                Secretary shall permit the applicant, \n                                to the extent that the Secretary \n                                determines it to be appropriate, to \n                                reference information submitted in the \n                                previous application.''.\n    (b) Conforming Amendments.--Section 505A of the Federal Food, Drug, \nand Cosmetic Act (21 U.S.C. 355a) is amended--\n            (1) in subsections (b)(1)(A)(i) and (c)(1)(A)(i), by \n        striking ``(j)(5)(D)(ii)'' each place it appears and inserting \n        ``(j)(5)(F)(ii)'';\n            (2) in subsections (b)(1)(A)(ii) and (c)(1)(A)(ii), by \n        striking ``(j)(5)(D)'' each place it appears and inserting \n        ``(j)(5)(F)''; and\n            (3) in subsections (e) and (l), by striking \n        ``505(j)(5)(D)'' each place it appears and inserting \n        ``505(j)(5)(F)''.\n\nSEC. 3. FORFEITURE OF 180-DAY EXCLUSIVITY PERIOD.\n\n    Section 505(j)(5) of the Federal Food, Drug, and Cosmetic Act (21 \nU.S.C. 355(j)(5)) (as amended by section 2) is amended--\n            (1) in subparagraph (B)(iv), by striking subclause (II) and \n        inserting the following:\n                                    ``(II) the earlier of--\n                                            ``(aa) the date of a final \n                                        decision of a court in a civil \n                                        action described in clause \n                                        (iii) from which no appeal has \n                                        been or can be taken; or\n                                            ``(bb) the date of a \n                                        settlement order or consent \n                                        decree signed by a Federal \n                                        judge that enters a final \n                                        judgment and includes a finding \n                                        that the patent that is the \n                                        subject of the certification is \n                                        invalid or not otherwise \n                                        infringed;''; and\n            (2) by inserting after subparagraph (C) the following:\n                    ``(D) Forfeiture of 180-day exclusivity period.--\n                            ``(i) In general.--The 180-day exclusivity \n                        period described in subparagraph (B)(iv) shall \n                        be forfeited if the applicant--\n                                    ``(I) fails to market the drug \n                                within 30 days after the date on which \n                                the approval of the application for the \n                                drug is made effective under \n                                subparagraph (B)(iii);\n                                    ``(II) fails to market the drug--\n                                            ``(aa) within 30 days after \n                                        the date of a final decision of \n                                        a court or the date of a \n                                        settlement order or consent \n                                        decree in a civil action \n                                        described in subparagraph \n                                        (B)(iii); or\n                                            ``(bb) if the application \n                                        has not been approved before \n                                        the date of such a decision, \n                                        within 30 days after the date \n                                        of approval of the application;\n                                    ``(III) withdraws the application;\n                                    ``(IV) amends the application from \n                                a certification under paragraph \n                                (2)(A)(vii)(IV) to a certification \n                                under paragraph (2)(A)(vii)(III);\n                                    ``(V) fails to get tentative \n                                approval of the application within 30 \n                                months after the date on which the \n                                application is filed, if the failure is \n                                not caused by a change in the \n                                requirements for tentative approval of \n                                the application imposed after the date \n                                on which the application is filed; or\n                                    ``(VI) enters into an agreement \n                                with the owner of the patent--\n                                            ``(aa) that is the subject \n                                        of the certification under \n                                        paragraph (2)(A)(vii)(IV); and\n                                            ``(bb) that the Federal \n                                        Trade Commission determines has \n                                        violated the antitrust laws (as \n                                        defined in section 1 of the \n                                        Clayton Act (15 U.S.C. 12), \n                                        except that the term includes \n                                        section 5 of the Federal Trade \n                                        Commission Act (15 U.S.C. 45) \n                                        to the extent that that section \n                                        applies to unfair methods of \n                                        competition).\n                            ``(ii) Subsequent applicant.--If an \n                        applicant forfeits the 180-day exclusivity \n                        period under clause (i)--\n                                    ``(I) a subsequent application \n                                containing a certification period \n                                described in paragraph (2)(A)(vii)(IV) \n                                shall become effective immediately on \n                                approval; and\n                                    ``(II) the subsequent applicant \n                                shall not be eligible for a 180-day \n                                exclusivity period under subparagraph \n                                (B)(iv).''.\n\nSEC. 4. BIOEQUIVALENCE.\n\n    (a) In General.--The amendments to part 320 of title 21, Code of \nFederal Regulations, promulgated by the Commissioner of Food and Drugs \non July 17, 1991 (57 Fed. Reg. 17997 (April 28, 1992)), shall continue \nin effect as an exercise of authorities under sections 501, 502, 505, \nand 701 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 351, \n352, 355, 371).\n    (b) Effect.--Subsection (a) does not affect the authority of the \nCommissioner of Food and Drugs to amend part 320 of title 21, Code of \nFederal Regulations.\n\nSEC. 5. OVER-THE-COUNTER DRUGS.\n\n    Section 503(b)(3) the Federal Food, Drug, and Cosmetic Act (21 \nU.S.C. 353(b)(3)) is amended--\n            (1) by striking ``(3) The Secretary may by regulation \n        remove drugs'' and inserting the following:\n            ``(3) Removal of certain drugs from requirements of \n        paragraph (1).--\n                    ``(A) In general.--The Secretary may by regulation \n                remove a drug''; and\n            (2) by adding at the end the following:\n                    ``(B) Misbranding.--A drug that is removed from the \n                requirements of paragraph (1) under subparagraph (A) \n                shall be deemed to be misbranded under paragraph (1) in \n                a case in which any person introduces the drug into \n                interstate commerce in accordance with the requirements \n                of paragraph (1).''."
}